These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31389789)

  • 1. Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis.
    Hou M; Xing H; Cai Y; Wang X; Xie Z; Zhang Q; Ma Y; Chen J
    Eur J Dermatol; 2019 Jun; 29(3):302-314. PubMed ID: 31389789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
    Xu S; Zhang X; Pan M; Shuai Z; Xu S; Pan F
    Int Immunopharmacol; 2019 Oct; 75():105841. PubMed ID: 31465912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tildrakizumab for the treatment of psoriasis.
    Sinclair R; Thirthar Palanivelu V
    Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
    Attia A; Abushouk AI; Ahmed H; Gadelkarim M; Elgebaly A; Hassan Z; Abdel-Daim MM; Negida A
    Clin Drug Investig; 2017 May; 37(5):439-451. PubMed ID: 28197901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials.
    Wu D; Hou SY; Zhao S; Hou LX; Jiao T; Xu NN; Zhang N
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):992-1003. PubMed ID: 28107570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
    J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
    Yiu ZZ; Warren RB
    Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials.
    Qiu Y; Zhu Y; Liu Y; Liu Q
    J Dermatolog Treat; 2023 Dec; 34(1):2199106. PubMed ID: 37010492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis.
    Zhu T; Ma L
    Contrast Media Mol Imaging; 2022; 2022():2172980. PubMed ID: 35845729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific targeting of interleukin-23p19 as effective treatment for psoriasis.
    Levin AA; Gottlieb AB
    J Am Acad Dermatol; 2014 Mar; 70(3):555-61. PubMed ID: 24373779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.